公开(公告)号：US20220305119A1

公开(公告)日：2022-09-29

申请号：US17616971

申请日：2020-06-05

Applicant: Dana-Farber Cancer Institute, Inc. ,  Korea Institute of Science and Technology ,  PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Inventor： William M. Shih ,  Ju Hee Ryu ,  Yang Zeng

IPC: A61K39/39 ,  A61K47/54 ,  A61K47/60 ,  A61K47/64 ,  A61K9/00 ,  A61K9/06

Abstract: Provided herein, in some embodiments, are nucleic acid nanostructure-based vaccines.

公开(公告)号：US11618916B2

公开(公告)日：2023-04-04

申请号：US16568363

申请日：2019-09-12

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Ick Chan Kwon ,  Ju Hee Ryu ,  Young-Ji Ko ,  Hye-Sun Kim ,  Nam-Hyuk Cho ,  Eun-Jeong Yang ,  Jae Won Lee

IPC: C12Q1/37 ,  G01N33/573

Abstract: A probe for measuring the activity of caspase-1 according to the present disclosure can specifically image cells or tissues where inflammatory response is induced because it is cleaved by reacting specifically with the active caspase-1 enzyme in vivo and in vitro and re-emits fluorescence. The probe for measuring the activity of caspase-1 can be used for various purposes, such as for imaging of cells or tissues where inflammatory response is induced, as a drug carrier, for screening of a drug inhibiting inflammatory response, etc.
The probe for measuring the activity of caspase-1 is applicable both in vivo and in vitro, and can be used for various applications such as high-throughput screening for new drug development, early diagnosis of diseases, etc.

公开(公告)号：US11498946B2

公开(公告)日：2022-11-15

申请号：US17118767

申请日：2020-12-11

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung Kim ,  Ju Hee Ryu ,  Hong Yeol Yoon ,  Man Kyu Shim ,  Suah Yang

IPC: C07K14/47 ,  A61P35/00 ,  A61K47/10 ,  C07K16/28 ,  A61K47/64

Abstract: The present disclosure relates to a pharmaceutical composition for combination therapy for preventing or treating cancer, which contains a first pharmaceutical ingredient containing a drug conjugate wherein an anticancer agent is bound at one end of an amphiphilic peptide represented by SEQ ID NO 1 and a poloxamer; and a second pharmaceutical ingredient containing an anti-PD-L1 antibody; as active ingredients. The pharmaceutical composition significantly inhibits cancer growth in in-vivo experiments and exhibits an effect of significantly enhancing immunotherapeutic effect by activating immune cells in cancerous tissues.
In particular, the pharmaceutical composition for combination therapy according to the present disclosure has superior tumor accumulation efficiency and selectivity as compared to existing anticancer agents, and is very stable with little toxicity to normal tissues other than cancerous tissues.

公开(公告)号：US20170112910A1

公开(公告)日：2017-04-27

申请号：US15299993

申请日：2016-10-21

Applicant: Korea University Research And Business Foundation ,  Korea Institute of Science and Technology

Inventor： Jeewon Lee ,  Bo Ram Lee ,  Kwangmeyung Kim ,  Ju Hee Ryu ,  Ho Kyung Ko

IPC: A61K39/00

CPC classification number: A61K39/0011 ,  A61K9/5169 ,  A61K2039/55555 ,  A61K2039/6031 ,  B82Y5/00

Abstract: The present invention relates to a protein nanoparticle having a surface on which a cancer-specific epitope is fused and expressed, a method for producing the same, and a composition for cancer immunotherapy containing the protein nanoparticle as an active ingredient, and more specifically, to a recombinant microorganism into which a vector in which a promoter, a gene of a human ferritin heavy chain protein, and a gene encoding the cancer-specific epitope are operably linked is introduced, a protein nanoparticle in which a cancer-specific epitope is fused and expressed on a surface of the human ferritin heavy chain protein, a method of producing the protein nanoparticle, and a composition for cancer immunotherapy including the protein nanoparticle as the active ingredient, wherein the cancer-specific epitope on the surface of the protein nanoparticle according to the present invention is able to be expressed with correct orientation and high density, and the composition for cancer immunotherapy including the protein nanoparticle as the active ingredient has significantly excellent cancer immunotherapeutic effect as compared to the existing nanoparticle-based composition.

公开(公告)号：US10213515B2

公开(公告)日：2019-02-26

申请号：US15169493

申请日：2016-05-31

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung Kim ,  Ju Hee Ryu ,  Ick Chan Kwon ,  Man Kyu Shim ,  Hong Yeol Yoon

IPC: A61K51/00 ,  A61M36/14 ,  A61K49/00 ,  C07K9/00 ,  G01N33/574 ,  G01N33/58 ,  C07K5/11 ,  C07K5/107 ,  A61K47/54

Abstract: The present disclosure relates to a glycopeptide targeting cancer cells and a contrast agent kit containing the same. The glycopeptide is one wherein an azide reporting monosaccharide is bound to a substrate peptide. As the substrate peptide is specifically cleaved by cathepsin B in cancer cells, an azide reporting monosaccharide is expressed onto the cell surface via metabolic glycoengineering, thereby providing a target for action as a contrast agent. Accordingly, because the azide is exposed to the cell surface only by cathepsin B, as it is specifically expressed in cancer cells, in particular in metastatic cancer cells, while it is limitedly expressed in normal cells and is hardly excreted out the cells, the cancer cells can be selectively imaged by an azide-specific contrast agent.

公开(公告)号：US10206987B2

公开(公告)日：2019-02-19

申请号：US15299993

申请日：2016-10-21

Applicant: Korea University Research And Business Foundation ,  Korea Institute of Science and Technology

Inventor： Jeewon Lee ,  Bo Ram Lee ,  Kwangmeyung Kim ,  Ju Hee Ryu ,  Ho Kyung Ko

IPC: A61K39/00 ,  A61K9/14 ,  B82Y5/00

Abstract: The present invention relates to a protein nanoparticle having a surface on which a cancer-specific epitope is fused and expressed, a method for producing the same, and a composition for cancer immunotherapy containing the protein nanoparticle as an active ingredient, and more specifically, to a recombinant microorganism into which a vector in which a promoter, a gene of a human ferritin heavy chain protein, and a gene encoding the cancer-specific epitope are operably linked is introduced, a protein nanoparticle in which a cancer-specific epitope is fused and expressed on a surface of the human ferritin heavy chain protein, a method of producing the protein nanoparticle, and a composition for cancer immunotherapy including the protein nanoparticle as the active ingredient, wherein the cancer-specific epitope on the surface of the protein nanoparticle according to the present invention is able to be expressed with correct orientation and high density, and the composition for cancer immunotherapy including the protein nanoparticle as the active ingredient has significantly excellent cancer immunotherapeutic effect as compared to the existing nanoparticle-based composition.

公开(公告)号：US09409923B2

公开(公告)日：2016-08-09

申请号：US13936768

申请日：2013-07-08

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwang Meyung Kim ,  Ick Chan Kwon ,  Sang Yoon Kim ,  Ju Hee Ryu ,  Eun Sung Jun ,  In San Kim

IPC: C07D499/78 ,  C07D209/62 ,  C07D409/14 ,  C07D498/08

CPC classification number: C07D499/78 ,  C07D209/62 ,  C07D409/14 ,  C07D498/08

Abstract: Disclosed is a drug-fluorophore complex for specific detection of tumor cells. Specifically, the drug-fluorophore complex includes a tumor cell-targeting drug penetrating tumor cells and non-tumor cells at different rates or levels, and a fluorescent substance chemically bonded to the tumor cell-targeting drug. The drug-fluorophore complex enables specific imaging of tumor cells only with high accuracy in a very simple manner without causing cytotoxicity.

Abstract translation: 公开了用于特异性检测肿瘤细胞的药物 - 荧光团复合物。 具体地，药物 - 荧光团复合物包括以不同速率或水平渗透肿瘤细胞和非肿瘤细胞的肿瘤细胞靶向药物和与肿瘤细胞靶向药物化学键合的荧光物质。 药物荧光团复合物能够以非常简单的方式以高精度进行肿瘤细胞的特异性成像，而不引起细胞毒性。